where its at

I like the idea of reducing the company to just a PO Box.

Up front fees for SpeeDx I believe are low but the market for the TB products is enormous because this technology is at the relatively lower end which of course is appealing to nations with limited budgets. These are the very countries with highest rates of TB and the greatest demand. That's a huge advantage and any commercialisation would produce instant results on the market price.

Neoclone is unknown but research uptake is critical as a first step..then any advance is dealt with direct by TDX again looking at commercialisation.

Bayer....TDX should give us an indication of the source of claim. ie what terms do they believe have been broken and what is the financial implication? Has the negotiation with Bayer been favourable to date? One would imaging if TDX were commissioned to produce readrite in four languages, then shortly after the pin is pulled, there may be a substantial compensation payment.